Back to top
more

Syneos Health (SYNH)

(Delayed Data from NSDQ)

$37.58 USD

37.58
1,086,977

-0.35 (-0.92%)

Updated Feb 6, 2023 04:00 PM ET

After-Market: $37.59 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.28%
2Buy17.83%
3Hold9.19%
4Sell5.00%
5Strong Sell2.16%
S&P50010.51%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (161 out of 250)

Industry: Medical Info Systems

Trades from $1

Company Summary

Morrisville, NC based Syneos Health, Inc. is a key global biopharmaceutical solutions company offering a broad range of clinical and commercial facilities. The company majorly serves customers in the biopharmaceutical, biotechnology and medical device industries. Through its Contract Research Organization (CRO) and Contract Commercial Organization (CCO), it provides integrated and self-contained biopharmaceutical product development solutions varying from Early Phase (Phase I) clinical trials to complete commercialization of biopharmaceutical products.

Although incorporated as INC Research Holdings in August 2010, the company changed its name to Syneos Health after merging with inVentiv Health in 2017. ...

General Information

Syneos Health, Inc

1030 Sync Street

Morrisville, NC 27560

Phone: 919-876-9300

Fax: 919-876-9360

Web: http://www.syneoshealth.com

Email: investor.relations@syneoshealth.com

Industry Medical Info Systems
Sector Medical
Fiscal Year End December
Last Reported Quarter 12/31/2022
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

2/16/2023

EPS Information

Current Quarter EPS Consensus Estimate 1.21
Current Year EPS Consensus Estimate 4.70
Estimated Long-Term EPS Growth Rate NA
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

2/16/2023

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 37.93
52 Week High 92.58
52 Week Low 22.89
Beta 1.65
20 Day Moving Average 1,513,895.38
Target Price Consensus 42.45

SYNH

% Price Change
4 Week 8.59
12 Week 10.42
YTD 3.41
% Price Change Relative to S&P 500
4 Week 2.25
12 Week 6.59
YTD -4.02
Share Information
Shares Outstanding (millions) 102.90
Market Capitalization (millions) 3,903.15
Short Ratio NA
Last Split Date NA
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio 0.00
Change in Payout Ratio 0.00
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) 10.09
Trailing 12 Months 7.63
PEG Ratio NA
EPS Growth
vs. Previous Year 0.89%
vs. Previous Quarter 0.00%
   
Sales Growth
vs. Previous Year -0.89%
vs. Previous Quarter -1.80%
   
Price Ratios
Price/Book 1.16
Price/Cash Flow 6.03
Price / Sales 0.72
ROE
12/31/22 NA
9/30/22 14.01
6/30/22 14.04
ROA
12/31/22 NA
9/30/22 5.69
6/30/22 5.69
Current Ratio
12/31/22 NA
9/30/22 1.14
6/30/22 1.10
Quick Ratio
12/31/22 NA
9/30/22 1.14
6/30/22 1.10
Operating Margin
12/31/22 NA
9/30/22 8.68
6/30/22 8.66
Net Margin
12/31/22 NA
9/30/22 5.31
6/30/22 5.13
Pre-Tax Margin
12/31/22 NA
9/30/22 7.22
6/30/22 6.91
Book Value
12/31/22 NA
9/30/22 32.67
6/30/22 32.43
Inventory Turnover
12/31/22 NA
9/30/22 NA
6/30/22 NA
Debt-to-Equity
12/31/22 NA
9/30/22 0.84
6/30/22 0.86
Debt to Capital
12/31/22 NA
9/30/22 45.52
6/30/22 46.22